Old Web
English
Sign In
Acemap
>
authorDetail
>
Sergio Santillana
Sergio Santillana
Takeda Pharmaceutical Company
Gastroenterology
Internal medicine
Immunology
Medicine
Carboplatin
5
Papers
2
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia
2017
Clinical Lymphoma, Myeloma & Leukemia
Jorge E. Cortes
Hagop M. Kantarjian
Javier Pinilla-Ibarz
Philipp le Coutre
Ronald Paquette
Charles Chuah
Franck E. Nicolini
Moshe Talpaz
Michele Baccarani
Michael W. Deininger
Andreas Hochhaus
Timothy P. Hughes
Neil P. Shah
Stephanie Lustgarten
Sergio Santillana
Victor M. Rivera
Tim Clackson
Martin C. Mueller
Show All
Source
Cite
Save
Citations (0)
The OMNI Patient Registry: A Prospective, Observational, Non-Interventional Registry to Evaluate Vascular Safety of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
2017
Clinical Lymphoma, Myeloma & Leukemia
Annette Stemhagen
Deyaa Adib
Stephanie Lustgarten
Lisa McGarry
Ruth du Moulin
Sergio Santillana
Show All
Source
Cite
Save
Citations (1)
Investigational NEDD8-activating enzyme inhibitor pevonedistat (Pev) plus chemotherapy in patients (Pts) with solid tumors (Phase 1b study): Antitumor activity of pev plus carboplatin (Carbo)/paclitaxel (Pac).
2016
Journal of Clinical Oncology
Todd Michael Bauer
R. Donald Harvey
Carrie B. Lee
Charu Aggarwal
Roger B. Cohen
Farhad Sedarati
Zhaoyang Teng
Hélène M. Faessel
Ajeeta B Dash
Bruce J. Dezube
Sergio Santillana
Afshin Dowlati
Albert C. Lockhart
Show All
Source
Cite
Save
Citations (0)
Abstract B148: Population pharmacokinetics (PK) of the investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) administered alone or in combination with azacitidine in patients (pts) with solid or hematologic malignancies
2015
Molecular Cancer Therapeutics
Hélène M. Faessel
Diane R. Mould
Bruce J. Dezube
Sergio Santillana
Karthik Venkatakrishnan
Show All
Source
Cite
Save
Citations (1)
Abstract B26: Phase 1b trial of investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in combination with docetaxel, paclitaxel/carboplatin, or gemcitabine in patients (pts) with solid tumors
2015
Molecular Cancer Therapeutics
A. Craig Lockhart
Todd Michael Bauer
R. Donald Harvey
Carrie B. Lee
Charu Aggarwal
Roger B. Cohen
Farhad Sedarati
Ling Wang
Hélène M. Faessel
Bruce J. Dezube
Sergio Santillana
Afshin Dowlati
Show All
Source
Cite
Save
Citations (0)
1